Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05465083
Other study ID # 22-5815
Secondary ID 21-5516
Status Completed
Phase N/A
First received
Last updated
Start date February 4, 2023
Est. completion date November 10, 2023

Study information

Verified date June 2023
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center proof-of-concept clinical trial designed to establish the feasibility of transvenous phrenic-nerve stimulation (PNS) to maintain diaphragm activation over the first 24 hours and for up to seven days of mechanical ventilation in patients who are likely to require more than 48 hours of invasive mechanical ventilation.


Description:

The diaphragm is the main muscle of breathing and for most of us therefore is continuously being used (and hence exercised) when in health. When people are unwell with severe breathing difficulties to the degree that their lungs are needing a lot of support from a breathing machine (ventilator) in the intensive care unit (ICU), or are recovering from major lung/chest surgery on a ventilator in ICU, the diaphragm can quickly start to weaken from its inactivity. This means that even when starting to recover from the underlying medical problem, or from the surgery itself, the diaphragm may be unable perform well enough to take over the work of breathing once again. This can lead to not only longer times on the ventilator (time to gradually rebuild diaphragm strength by rehabilitation and physiotherapy) but also therefore longer times in ICU and in hospital with the risk of complications that can be associated with this. Stimulating the diaphragm by use of a pacemaker (electrical stimulation) is an established treatment for a number of patients with certain types of long-term breathing problems. These pacemakers are permanent and are inserted by invasive surgical methods. More recently however, there have also been a number of studies looking to see if it is possible to safely, temporarily and less invasively stimulate the diaphragm of patients who only have temporary diaphragm inactivity. This has been done either during surgery or during their intensive care stay. A number of methods of temporarily stimulating the diaphragm have been looked at, but the simplest has been to integrate the function of stimulating the nerves (that ultimately control the diaphragm) with a catheter that is frequently placed into a vein in the neck to enable delivery of medications during surgery and in ICU.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 10, 2023
Est. primary completion date October 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Group 1: Acute hypoxemic respiratory failure (AHRF) Inclusion Criteria: - Age =18 years old, and, - Invasive mechanical ventilation for = 7 days, and, - Have hypoxemia as defined by one of: - A PaO2:FiO2 ratio < 300 and PEEP = 5 cm H2O, or - SpO2:FiO2 < 315% on PEEP = 5 cm H2O in absence of an available arterial blood gas, and in the presence of a reliable Sp)2 trace and a SpO2 < 97%, or - Are receiving inhaled nitric oxide for acute hypoxemia, or - Require extracorporeal membrane oxygenation, and, - Are on controlled mechanical ventilation with no patient-triggered ventilator-delivered breaths with no imminent plan to transition to assisted ventilation within 6 hours, and, - Are not expected to be liberated from mechanical ventilation within the next 48 hours (from time of enrollment) Group 2: Pulmonary endarterectomy Inclusion Criteria: - Age 18 to 65 years old - Are listed for pulmonary thromboendarterectomy - Have pulmonary vascular resistance < 1000 dynes.sec.cm-5 Group 3: Lung transplant Inclusion Criteria: - Age 18 years or older - Are listed for bilateral lung transplant for a primary indication of idiopathic pulmonary fibrosis with no plan for concomitant transplant of other solid organs All groups Exclusion Criteria: - Pregnant or lactating - Previously diagnosed neuromuscular disorder or known phrenic nerve injury - BMI >70kg/m2 - Implanted electronic cardiac or neurostimulation device in situ - Contraindications to left internal jugular or subclavian vein catheterization (e.g., infection over the site, known central venous stenosis, septic thrombophlebitis, left internal jugular ECMO cannula in situ) and/or subclavian vein catheterization (to include poor target vessel) - Contraindications to esophageal balloon or EMG catheter placement (e.g. active bleeding or high-grade esophageal varices with recent bleeding or banding in previous 14 days, recent esophageal surgery or esophageal rupture) - Patient transitioning fully to palliative care - Treating clinician deem enrollment not clinically appropriate for other reason - Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lungpacer AeroPace Protect System
AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.

Locations

Country Name City State
Canada University Health Network Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto Lungpacer Medical Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of placing AeroPace Catheter Feasibility will be defined as the device being successfully deployed in at least 11 of the 20 patients. Successful deployment of the device defined as:
AeroPace Catheter insertion and placement successfully confirmed
Initial Catheter electrode mapping/calibration successfully completed
Adequate diaphragm activation achieved, defined as hourly Edi level sufficient to generate a Pocc of = -5 cm H2O, for at least 50% of LAPS-PNS stimulated breaths over the first 24 hours after commencing stimulation.
30 days
Primary Safety of AeroPace Catheter The technique will be considered safe if there are no unexpected serious adverse events (USADEs) and the incidence of device- or procedure-related SAEs is below that established in literature. 30 days
Secondary LAPS-PNS successfully achieved at the time of the mapping/calibration procedure on each of the subsequent days up to the end of the study intervention period 7 days
Secondary The proportion of time that adequate diaphragm activation is maintained during phrenic nerve stimulation and during the absence of phrenic nerve stimulation. This is defined as the percentage of hours the patient has an Edi = minimum Edi required to maintain Pocc = -5 cm H2O. 7 days
Secondary The proportion of hours in which the maintenance of diaphragm activation is due to LAPS-PNS rather than endogenous patient respiratory effort. 7 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06007495 - Pilot Physiological Evaluation of an Investigational Mask With Expiratory Washout. N/A
Completed NCT05060926 - Intubation Prediction in COVID-19 Patients Treated With Awake Prone Positioning
Recruiting NCT05203536 - Respiratory Mechanics Assessment During Assisted Mechanical Ventilation
Completed NCT04570384 - Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 Phase 2
Not yet recruiting NCT05499039 - High Flow Nasal Cannula Versus Non-Invasive (NIV)in Both Hypoxemic and Hypercapnic Respiratory Failure. N/A
Completed NCT04568642 - Comparing Closed-loop FiO2 Controller With Conventional Control of FiO2 N/A
Completed NCT03653806 - Automated Analysis of EIT Data for PEEP Setting
Completed NCT01747109 - Benefits of Optiflow® Device for Preoxygenation Before Intubation in Acute Hypoxemic Respiratory Failure : The PREOXYFLOW Study N/A
Terminated NCT04632043 - Early Versus Delayed Intubation of Patients With COVID-19 N/A
Completed NCT04581811 - Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) N/A
Not yet recruiting NCT06064409 - Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
Completed NCT03133520 - Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure N/A
Not yet recruiting NCT06438198 - Early Switch From Controlled to Assisted Ventilation N/A
Recruiting NCT04997265 - Strategies for Anticoagulation During Venovenous ECMO N/A
Completed NCT05083130 - Awake Prone Positioning in Moderate to Severe COVID-19 N/A
Active, not recruiting NCT06374589 - Closed-Loop O2 Use During High Flow Oxygen Treatment Of Critical Care Adult Patients (CLOUDHFOT) N/A
Active, not recruiting NCT06333002 - Machine Learning Model to Predict Outcome and Duration of Mechanical Ventilation in Acute Hypoxemic Respiratory Failure
Recruiting NCT05078034 - HNFO With or Without Helmet NIV for Oxygenation Support in Acute Respiratory Failure Pilot RCT N/A
Recruiting NCT03513809 - Inflammation and Distribution of Pulmonary Ventilation Before and After Tracheal Intubation in ARDS Patients
Terminated NCT04395807 - Helmet CPAP Versus HFNC in COVID-19 N/A